GIA Miami takes a team approach to treatment
GIA Miami's team supports all aspects of patient treatment to bolster the effectiveness of TMS
Dr. Jeremy Waletzky is a psychiatrist who has devoted his career to taking care of patients with depression and bipolar disease. Unfortunately, both frequently occur with addictions and all need to be treated. His expertise includes the use of medication and various forms of psychotherapy, including cognitive-behavior therapy, family therapy, meditation, and imagery. He is a clinical professor at The George Washington University and a distinguished life fellow of the American Psychiatric Association. He has published on topics as diverse as the clinical use of anti-psychotics, Soviet children and the threat of nuclear war, and the inability of an “energy” healer to distinguish between fertile and infertile women. Following the death of his son from a cocaine arrhythmia, along with the Society for Neuroscience he established the Jacob P. Waletzky Award along which honors the best mid career researcher in addiction. He received a lifetime achievement award by the National Institute of Drug Abuse.
Dr. Waletzky has had considerable foundation experience including being on the board of trustees and executive committee of the Rockefeller Family Fund, the Rockefeller Brothers Fund , and the Fetzer Memorial Trust. In addition, he was on the board of trustees and chairman of The Fetzer Institute.
Ms. Clampitt has completed six years of conservatory acting training and has served for many years as a consultant to arts-focused and other nonprofit organizations, a role that has involved building and strategic planning as well as board and program development. She held senior executive positions as Director of Arts and Humanities Presidential Appointments at the White House; Executive Director and General Manager of WAMU 88.5 in Washington DC, one of the country’s leading National Public Radio (NPR) stations; Deputy Chair for Programs at the National Endowment for the Arts; founder and chair of America’s first museum education graduate program; Associate Director of Media and Communications at New York’s Museum of Modern Art, and Curator at the Montclair Art Museum.
Appointed by three successive Washington DC mayors, Ms. Clampitt served as Commissioner on the DC Commission on the Arts and Humanities. She is a founding board member and Vice President of the Mosaic Theater Company of DC. She also serves regularly as a grants panelist for the National Endowment for the Arts. She is a recipient of the Fast 50 Award for entrepreneurship from Fast Company magazine and is a winner of the Mayor’s Arts Award for service to the arts.
A native of Athens, Greece, Dr. Lyketsos graduated from Athens College, Northwestern University and Washington University Medical School in St. Louis. He completed residency and Chief Residency in psychiatry at Johns Hopkins, as well as a fellowship in clinical epidemiology. An active clinician, teacher, and researcher he founded the Johns Hopkins Memory and Alzheimer’s Center which he directs. Dr. Lyketsos leads the Johns Hopkins Precision Medicine Center of Excellence on Alzheimer’s Disease, and is Associate Director of NIH-funded Alzheimer’s Disease Research Center.
A world authority in treatment development for Alzheimer’s, he has received multiple major awards, and authored over 400 peer-reviewed articles, chapters, commentaries, as well as five books. His work has been cited over 52,000 times with an h-index of 123 (Google Scholar). Castle-Connolly has named him as one of America’s Top Doctors every year since 2001.
Regarding his specific expertise on Mental Health, Dr. Lyketsos developed one of the largest and most successful academic neuropsychiatry programs in the USA. Prior to taking leadership of Johns Hopkins Bayview Psychiatry, he was co-director of the Johns Hopkins Division of Geriatric Psychiatry and Neuropsychiatry.
He has received numerous internationally recognized Honors and Awards, he is a member of the American Psychiatric Association, American Association for Geriatric Psychiatry, Academy of Psychosomatic Medicine, American College of Neuropsychopharmacology, American College of Psychiatrists, and an Associate Editor of American Journal of Psychiatry, Deputy Editor of International Psychogeriatrics, Editor of International Review of Psychiatry, and Lead Editor of Psychiatric Aspects of Neurologic Diseases: Practical Approaches to Patient Care.
Deborah Mash is the CEO and Founder of DemeRx, Inc., a clinical stage drug development company advancing ibogaine and its active metabolite noribogaine for the treatment of opioid use disorder. DemeRx partnered in 2019 with ATAI Life Sciences — a global biotech platform — to develop ibogaine for those suffering from opioid use disorder.
Deborah is a neuroscientist, lecturer, and inventor who has dedicated more than 30 years of research to unlocking the secrets of the human brain. She is nationally recognized as a leading neuroscience researcher, playing a pivotal role in over 300 published studies investigating aging, neurodegenerative and psychiatric disorders, drug development, and addiction neurobiology. She is the founder and former director of the University of Miami Brain Endowment Bank, one of the six NIH funded NeuroBioBanks. She has held uninterrupted Public Health Service NIH funding to advance research studies focused on the role of the human brain in health and disease.
Dr. Stefano Pallanti is a “Physician-Scientist” who applies cutting-edge neuroscience breakthroughs to clinical work by utilizing clinical activities to formulate research hypotheses. He is a NIMH grant co-PI in Theta Burst Stimulation of pathological gamblers.
Dr. Pallanti holds the position of Professor of Psychiatry at the University of Florence and Director of the Institute for Neurosciences in Italy as well as Professor of Psychiatry and Behavioral Sciences at Stanford University Medical Center in Stanford, CA, where he works as a TMS Consultant. He has also been Visiting Professor at Albert Einstein College of Medicine in New York, Visiting Professor at Imperial College, London, and Adjunct Associate Professor at Icahn School of Medicine at Mount Sinai, New York, where he also served as the Founder and Director of the Strategic Center of Excellence for OCD, Impulsive, and Behavioral Addiction.
Dr. Pallanti is an Executive Committee Member, the Chair of the Neuromodulation Network, and a member of the Scientific Board of the ECNP (European College of Neuropsychopharmacology) and also serves on its Educational Committee. He is the Advisory Council member of the International Center for Autism Research and Education (Icare4autism, New York), an international fellow, and served on the Advisory Board of the American Psychiatric Association for the Diagnostic and Statistical Manual of Mental Disorders, both for the DSM-IV and for the Obsessive-Compulsive Disorder Spectrum Workgroup for the DSM-V. He is a member of the board of directors of the International College for Obsessive-Compulsive Spectrum Disorders (ICOCS), a member of the PANDAS Physicians Network and of the International Neuroethics Society.
Since 2014 he has been a board member for the World Health Organization as an expert on anxiety. He served as a member of the board of directors of the Clinical TMS Society from May 2013 to May 2017. He is a member of the New York Society of Psychiatry. In 2019 Dr. Pallanti was appointed to the faculties of both the International Psychopharmacology Course of the Harvard University and Massachusetts General Hospital Psychiatry Academy and the Training School at Clare College, Cambridge University, UK for the European Network for Problematic Usage of the Internet.
He is particularly active in rTMS, Neuromodulation, Photo-Bio Modulation, and Vagus Nerve Stimulation covering a broad area of Neuropsychiatry. He is Editor of the Archive of Behavioral Addiction, and Deputy Editor of CNS Spectrums, where he is also a columnist. He has published 187 peer-reviewed papers as of April 2020, 12 books, four manuals of Psychiatry. His H index is 55 as of April 2020.